Bei Akademie registrieren
CVRX, US1266381052

CVRx stock faces key test with third-quarter results due November 5

Published on 11/05/2026 at 02:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CVRx stock enters a key earnings date as the medical-device company prepares its third-quarter report. Management will discuss the figures afterward.

CVRx prepares quarterly results

  • CVRx plans to publish third-quarter 2026 financial and operating results after the U.S. market closes on November 5.
  • Management is scheduled to discuss the figures during a conference call at 4:30 p.m. Eastern Time.
  • Barostim remains the company's central neuromodulation product for heart-failure patients.
CVRX, US1266381052, Illustration mit AI erstellt.
CVRX, US1266381052, Illustration mit AI erstellt.

CVRx announced on October 22 that it plans to release its third-quarter 2026 financial and operating results after the U.S. market closes on Thursday, November 5. The company will follow the release with a conference call at 4:30 p.m. Eastern Time, according to the CVRx announcement carried by GlobeNewswire.

Results set the next test

The report will give investors a fresh view of revenue development, operating execution and the company's outlook for the remainder of 2026. The subsequent call is scheduled to provide management's commentary on the quarterly figures and current business priorities.

CVRx's previous company update listed on its topic page said second-quarter revenue rose 16 percent to USD 15.70 million and placed 2026 revenue guidance at USD 58.00 million to USD 60.00 million. Those figures belong to the earlier reporting period and are not a substitute for the third-quarter results.

Barostim drives the business

CVRx develops, manufactures and commercializes neuromodulation solutions for cardiovascular diseases. Its principal product, Barostim, is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery and is designed to improve symptoms in patients with heart failure. The company sells through its own sales force, sales agents and independent distributors in the United States, Germany, other European markets and additional international territories.

CVRx is headquartered in Minneapolis, Minnesota, and operates in the Healthcare sector within Medical Devices. Its specialized focus is cardiovascular neuromodulation rather than a broad medical-device portfolio.

U.S. equities can be followed through the S&P 500 market overview.

More news and analyses on CVRx stock are available on the company topic page.

CVRx company profile

  • Company: CVRx, Inc.
  • ISIN: US1266381052
  • Ticker: CVRX
  • Sector: Healthcare
  • Industry: Medical Devices
  • Headquarters: Minneapolis, Minnesota, United States
  • Chief executive: Kevin Hykes
Disclaimer...
en | US1266381052 | CVRX | boerse | 70460269 |